sitagliptin + lansoprazole

Sitagliptin + lansoprazole is an oral combination of two approved small molecule drugs, sitagliptin and lansoprazole. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases insulin production and decreases glucagon secretion by the pancreas, primarily used for type 2 diabetes. Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, commonly used to treat gastrointestinal ulcers and gastroesophageal reflux disease. This combination has been investigated in clinical trials for its potential to preserve pancreatic β-cell function in patients with recent-onset type 1 diabetes, based on preclinical evidence suggesting both agents may enhance β-cell survival and regeneration[1][4]. The mechanism involves DPP-4 inhibition (sitagliptin) leading to increased incretin levels (such as GLP-1), while lansoprazole increases gastrin levels; both hormones are implicated in β-cell preservation.